3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
2
Status
Terminated
1
Recruiting
1
Sponsor Class
OTHER
6
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Classical hematology
7
Gastrointestinal
2
Thoracic
1
Conditions
Colorectal Neoplasms
1463
Pancreatic Neoplasms
833
Stomach Neoplasms
692
Carcinoma, Hepatocellular
647
Carcinoma, Non-Small-Cell Lung
542
Neoplasms
459
Breast Neoplasms
369
Ovarian Neoplasms
338
Neoplasm Metastasis
337
Colonic Neoplasms
332
Esophageal Neoplasms
297
Liver Neoplasms
266
Melanoma
255
Lung Neoplasms
246
Squamous Cell Carcinoma of Head and Neck
210
Cholangiocarcinoma
180
Carcinoma, Renal Cell
180
Prostatic Neoplasms
175
Head and Neck Neoplasms
172
Triple Negative Breast Neoplasms
163
Rectal Neoplasms
160
Endometrial Neoplasms
160
Uterine Cervical Neoplasms
155
Gastrointestinal Neoplasms
142
Urinary Bladder Neoplasms
139
Biliary Tract Neoplasms
135
Gastrointestinal Stromal Tumors
108
Sarcoma
105
Esophageal Squamous Cell Carcinoma
102
Small Cell Lung Carcinoma
95
Interventions
isoquercitrin
1
abelacimab
1
MAA868
1
Dalteparin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
INDUSTRY
×
Pulmonary Embolism
×
Gastrointestinal
×
Clear all
NCT05171075
2026-04-17
MAGNOLIA
Anthos Therapeutics, Inc.
Phase 3
Terminated
417 enrolled
NCT06861088
2026-02-02
CATIQ P3
Quercis Pharma AG
Phase 3
Recruiting
480 enrolled